Publications by authors named "Mohammad J Khalifeh"
Background: Surgery and systemic therapy provide the best option for long-term cancer control in localized resectable pancreas cancer. The present study assessed the efficacy and safety of neoadjuvant treatment with FOLFIRINOX in patients with borderline resectable (BR) and locally advanced (LA) pancreas cancer (PDAC).
Methods: This was a prospective noninterventional observational trial of neoadjuvant FOLFIRINOX in BR and LA PDAC.
The liver is the most commonly involved organ in the body by cystic echinococcosis (CE) secondary to infection with Echinococcus granulosus. In this article, the authors discuss the classification, recent advances in magnetic resonance (MR) imaging for the diagnosis of hepatic CE, and approaches for management of hepatic CE using five therapeutic options that include: antihelminthic chemotherapy, surgery, percutaneous treatment, endoscopic approach, and the "watch and wait" approach.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the effectiveness and safety of cervical exploration for patients with primary hyperparathyroidism (HPT), comparing asymptomatic and symptomatic cases.
- It involved a review of 139 patients over a decade, analyzing factors such as symptoms, calcium and parathormone (PTH) levels, and surgical outcomes.
- Results indicated a high success rate for the surgery (98% immediate, 95.4% long-term), with lower PTH levels and adenoma weight in asymptomatic patients, highlighting that the procedure is safe and effective for both groups.
Background: To study the pharmacokinetics and clinical outcome of gemcitabine (2'-2'-difluoro-deoxcytidine [dFdC]) during intra-arterial versus intravenous delivery in locally advanced and regionally metastatic pancreatic cancer.
Patients And Methods: Seven patients with unresectable pancreatic cancer received escalating intra-arterial doses of gemcitabine ranging from 800 to 1400 mg/m2, after selective embolisation of all pancreatic blood supply, except for the tumour-feeding arteries. Four patients received intravenous gemcitabine (control).